Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
[This corrects the article DOI: 10.3389/fimmu.2019.01151.].
References
1.
Moll G, Hult A, Von Bahr L, Alm J, Heldring N, Hamad O
. Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells?. PLoS One. 2014; 9(1):e85040.
PMC: 3890285.
DOI: 10.1371/journal.pone.0085040.
View
2.
George M, Prabhakara K, Toledano-Furman N, Wang Y, Gill B, Wade C
. Clinical Cellular Therapeutics Accelerate Clot Formation. Stem Cells Transl Med. 2018; 7(10):731-739.
PMC: 6186273.
DOI: 10.1002/sctm.18-0015.
View
3.
Moll G, Ankrum J, Kamhieh-Milz J, Bieback K, Ringden O, Volk H
. Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. Trends Mol Med. 2019; 25(2):149-163.
DOI: 10.1016/j.molmed.2018.12.006.
View